In 2018, the Canadian Cancer Trials Group (CCTG) and CRI launched a multi-year collaboration to develop and conduct clinical trials in immunotherapy. The collaboration leverages comprehensive clinical trial designs such as umbrella and basket platforms to more efficiently evaluate emerging therapies, to better adapt to the ever-shifting immuno-oncology landscape, and to speed the delivery of clinical trials. By uniting CRI’s 65-year legacy and expertise in cancer immunology with CCTG’s cancer research expertise and global footprint, the collaboration hopes to accelerate the approval of better treatments for cancer patients around the world.
CCTG is a collaborative network of researchers, physicians, scientists, and statisticians globally recognized for finding the treatments that give people with cancer longer, better quality lives. Created in 1980, the internationally recognized group has conducted over 500 trials in over 40 countries, resulting in major, lifesaving breakthroughs in breast, colorectal, blood, lung, ovarian, brain, and prostate cancer. They are Canada's largest cancer clinical trials cooperative with over 80 member institutions and a network of 2,100 investigators.
View the CRI-CCTG Scientific Leadership Committee.